oct ~ 1 2003 KOSI440 Ae L
510(K) Summar
Submitter: Cynosure, Inc.
10 Elizabeth Drive
Chelmsford, MA 01824

Contact: George Cho
Senior Vice President of Medical Technology

Date Summary Prepared: May 5, 2003

Device Trade Name: Smart CO,

Common Name: Medical Laser System

Classification Name: Instrument, surgical, powered, laser
79-GEX
21 CFR 878.48

Equivalent Device: Luxar NovaPulse and Asclepion Multipulse

Device Description: Smart CO, is a CO, laser, having a sealed CO, gas tube as the lasing
medium. It is a laser with a wavelength of 10.6 pm.

Laser activation is by foot switch. Overall weight of the laser is 25
Kg, and the size is 180x62x42 cm (HxWxD).
Electrical requirement is 110 VAC, 15A, 50-60 Hz, single phase.

Intended Use: The Smart CO, laser is indicated for incision, excision, ablation,
vaporization and coagulation of body soft tissues including intraoral
tissues.

Comparison: The Smart CO, laser is substantially equivalent to the Luxar
NovaPulse and Asclepion Multipulse laser, with the same principle of
operation, the same wavelength and essentially the same power range
as the predicate devices for the same indications for uses.

Nonclinical Performance Data: none

Clinical Performance Data: none

Conclusion: The Smart CO, laser is another safe and effective device for body soft
tissue, including intraoral soft tissue applications.

Additional Information: none

2 ge DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
at Food and Drug Administration
9200 Corporate Boulevard
OCT . 1 2003 Rockville MD 20850
Mr. George Cho
Senior Vice President of Medical Technology
Cynosure, Inc.
10 Elizabeth Drive
Chelmsford, Massachusetts 01824
Re: K031440
Trade/Device Name: Smart CO) Laser
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for use in general and
plastic surgery and in dermatology
Regulatory Class: I
Product Code: GEX
Dated: August 22, 2003
Received: August 25, 2003
Dear Mr. Cho:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food. Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. ‘Ihe
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class 1 (Special Controls) or class ILI (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device m the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation contro! provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 - Mr. George Cho
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled,
"Misbranding by reference to premarket notification” (21CFR Part 807.97). You may obtain
other genera! information on your responsibilities under the Act from the Division of Small
Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or
(301) 443-6597 or at its Internet address hitp://www.fda.gov/cdrh/dsma/dsmamain.html]

Sincerely yours,

Wuane C Prevorwt

{ Celia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices

Office of Device Evaluation

Center for Devices and Radiological Health
‘Enclosure

510(k) Number (ifknown): KO S| 440)
Device Name: Smart CO, (Smart US 20D. Smart Clinic) Laser
Indications For Use:
The Smart CO, surgical laser is indicated for the incision, excision, ablation, vaporization and
coagulation of body soft tissues including intraoral tissues, in the medical specialties of general and
plastic surgery, oral/maxillofacial surgery, dentistry, dermatology, endoscopic/laproscopic general
surgery, gastroenterology, gynecology, otorhinolaryngology, neurosurgery, oculoplastic, orthopedic,
pulmonary/thoracic surgery, and urology for surgical and aesthetic applications.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
: Concurrence of CDRH, Office of Device Evaluation (ODE)
Mewapy & Droveat
(Wivision Sign-Off)
Division of General, Restorative
and Neurological Devices 510(k) Number__ 83/440 _
Prescription Use__|/ OR Over-The-Counter Use.
(Optional Format 1-2-96)

